Albania
Bośnia i Hercegowina
Bułgaria
Chorwacja
Cypr
Czarnogóra
Czechy
Dania
Estonia
Hiszpania
Kosowo
Litwa
Łotwa
Luksemburg
Macedonia
Niemcy
Polska
Portugalia
Rumunia
Serbia
Słowacja
Słowenia
Szwajcaria
Szwecja
Turcja
Węgry
Wielka Brytania
Włochy
UAE
Hong Kong
Kuwejt
Liban
RPA
Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 1001 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1002 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 1003 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1004 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 19 |
| 1005 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1006 | Apheresis | Allogeneic | Mixed Phenotype Acute Leukemia | Hematology | 2025 | Standard Therapy | Poland | 47 |
| 1007 | Apheresis | Allogeneic | Polycythemia Vera | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 1008 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 1009 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 53 |
| 1010 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 55 |
| 1011 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Poland | 34 |
| 1012 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 50 |
| 1013 | Apheresis | Allogeneic | Myelodysplastic Disorders | Hematology | 2025 | Standard Therapy | Poland | 71 |
| 1014 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | Poland | 64 |
| 1015 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 54 |
| 1016 | Apheresis | Autologous | Non-Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1017 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1018 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 35 |
| 1019 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 54 |
| 1020 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 52 |
| 1021 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1022 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 55 |
| 1023 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1024 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1025 | Apheresis | Allogeneic | Primary myelofibrosis | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1026 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 47 |
| 1027 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1028 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1029 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 44 |
| 1030 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 59 |
| 1031 | Apheresis | Autologous | Lymphoma Non-Hodgkin | Hematology | 2025 | Standard Therapy | Portugal | 58 |
| 1032 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 59 |
| 1033 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 2 |
| 1034 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 41 |
| 1035 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | France | 48 |
| 1036 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 64 |
| 1037 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | United Kingdom | 63 |
| 1038 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 64 |
| 1039 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 1040 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Poland | 68 |
| 1041 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Germany | 59 |
| 1042 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 1043 | Apheresis | Allogeneic | Diffuse Large B-cell Lymphoma | Hematology | 2025 | Standard Therapy | Belarus | 53 |
| 1044 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 60 |
| 1045 | Apheresis | Allogeneic | Immunodeficiency – LRBA | Hematology | 2025 | Standard Therapy | Turkey | 14 |
| 1046 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 20 |
| 1047 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1048 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 54 |
| 1049 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 75 |
| 1050 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 1051 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 48 |
| 1052 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 37 |
| 1053 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Chile | 40 |
| 1054 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1055 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Switzerland | 65 |
| 1056 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Portugal | 68 |
| 1057 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Estonia | 9 |
| 1058 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 63 |
| 1059 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 67 |
| 1060 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 45 |
| 1061 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 59 |
| 1062 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 69 |
| 1063 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1064 | Apheresis | Allogeneic | Acute lymphoblastic leukemia | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1065 | Apheresis | Autologous | Primary central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1066 | Apheresis | Allogeneic | Myelodysplastic Syndrome/ Acute Myeloid Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1067 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1068 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 55 |
| 1069 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1070 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1071 | Apheresis | Autologous | Central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1072 | Apheresis | Autologous | Follicular lymphoma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1073 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1074 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1075 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 64 |
| 1076 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 63 |
| 1077 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1078 | Apheresis | Autologous | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1079 | Apheresis | Autologous | Hodgkin lymphoma rezidiv | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1080 | Apheresis | Autologous | Non-Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1081 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1082 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1083 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1084 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1085 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 1086 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 55 |
| 1087 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 60 |
| 1088 | Apheresis | Allogeneic | Fanconi’s Anemia | Hematology | 2025 | Standard Therapy | Ukraine | 6 |
| 1089 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1090 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Lithuania | 54 |
| 1091 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Macedonia | 56 |
| 1092 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | CROATIA | 64 |
| 1093 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 75 |
| 1094 | Apheresis | Allogeneic | T-cell Lymphoma | Hematology | 2025 | Standard Therapy | NETHERLANDS | 65 |
| 1095 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1096 | Apheresis | Allogeneic | Myeloid Sarcoma | Hematology | 2025 | Standard Therapy | Brazil | 48 |
| 1097 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 17 |
| 1098 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | United Kingdom | 13 |
| 1099 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1100 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 13 |